Factor XIa inhibitors cut recurrent stroke without extra bleeding

Design

Systematic review and meta-analysis of three randomised placebo-controlled trials

Population

14,239 patients after noncardioembolic ischaemic stroke or TIA

Primary outcome

Recurrent stroke and major bleeding

Effect

Any stroke risk ratio 0.75 (95% CI 0.66-0.84); major bleeding 1.12 (0.87-1.44)

Patients remain at high risk of recurrent events after a noncardioembolic ischaemic stroke or TIA despite antiplatelet therapy, and anticoagulation has usually meant unacceptable bleeding. Factor XIa inhibitors are designed to reduce thrombosis while largely sparing haemostasis. This meta-analysis pooled three randomised placebo-controlled trials, 14,239 patients, to test the idea.

Added to antiplatelet therapy, factor XIa inhibitors reduced any stroke by a quarter (risk ratio 0.75), ischaemic stroke similarly (0.74) and composite cardiovascular events (0.83). Crucially, major bleeding was not significantly increased (risk ratio 1.12), nor were intracranial or any bleeding or mortality. The estimates are driven heavily by a single large phase 3 trial.

If borne out, this is the antithrombotic advance stroke prevention has been waiting for: a reduction in recurrence without the bleeding penalty of conventional anticoagulation. The class is not yet approved for this use, so the practical step is to anticipate it rather than prescribe it.

• Meta-analysis of three randomised placebo-controlled trials, 14,239 patients after noncardioembolic stroke or TIA.
• Added to antiplatelets, factor XIa inhibitors cut any stroke by a quarter (risk ratio 0.75).
• Ischaemic stroke fell similarly (0.74) and composite cardiovascular events too (0.83).
• Major bleeding was not significantly increased (risk ratio 1.12).
• The class is not yet approved for this indication, so anticipate rather than prescribe.

Why it matters

It offers the long-sought goal of less recurrent stroke without the bleeding cost of standard anticoagulation.

Don't overread it

The pooled estimate rests heavily on one phase 3 trial of an unapproved class; this is a strong signal, not yet an approved or guideline-endorsed therapy.

The statistics, in plain English

A risk ratio of 0.75 for any stroke, with a confidence interval of 0.66 to 0.84 entirely below 1.0, is a clear benefit unlikely to be chance. The bleeding risk ratio of 1.12 has a confidence interval (0.87 to 1.44) that crosses 1.0, so no meaningful excess bleeding was detected, though larger numbers could refine this.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.